Omalizumab
- Generic Name
- Omalizumab
- Brand Names
- Xolair, Omlyclo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 242138-07-4
- Unique Ingredient Identifier
- 2P471X1Z11
- Background
Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids . Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated . In September 2018, a new prefil...
- Indication
This drug is an anti-IgE antibody indicated for:
- Associated Conditions
- Chronic Idiopathic Urticaria, Moderate Asthma, Severe Asthma
- Associated Therapies
- -
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT01007149
- Locations
- 🇫🇷
Novartis Investigative Site, Toulouse, France
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 19
- Registration Number
- NCT01003301
- Locations
- 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States
Xolair Treatment for Milk Allergic Children
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00968110
- Locations
- 🇺🇸
Children's Hosptial Boston, Boston, Massachusetts, United States
🇺🇸Stanford Uneiversity Medical Center, Stanford, California, United States
Omalizumab in the Treatment of Peanut Allergy
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 51
- Registration Number
- NCT00949078
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
- Conditions
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 13
- Registration Number
- NCT00932282
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 271
- Registration Number
- NCT00870584
- Locations
- 🇺🇸
Palm Spring Research Institute, Inc, Hialeah, Florida, United States
🇺🇸Paul A Shapero, MD, Bangor, Maine, United States
🇺🇸Pediatric Pulmonary Associates of North Texas, PA, Dallas, Texas, United States
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00866788
Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT00822783
- Locations
- 🇦🇹
Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Austria., Vienna, Waehringer Guertel 18-20, Austria
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
- Conditions
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT00787917
- Locations
- 🇬🇧
Novartis Investigator Site, London, United Kingdom
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2013-10-01
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 49
- Registration Number
- NCT00657891
- Locations
- 🇺🇸
Creighton University Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.